BIOLASE, Inc. (NASDAQ:BIOL) Short Interest Down 74.1% in April

BIOLASE, Inc. (NASDAQ:BIOL) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 592,700 shares, a decline of 74.1% from the March 31st total of 2,290,000 shares. Currently, 1.9% of the shares of the company are sold short. Based on an average trading volume of 5,510,000 shares, the short-interest ratio is currently 0.1 days.

BIOLASE Stock Performance

BIOL stock remained flat at $0.15 during midday trading on Thursday. 612,965 shares of the company’s stock were exchanged, compared to its average volume of 4,498,681. BIOLASE has a 1-year low of $0.13 and a 1-year high of $32.09. The firm has a 50 day moving average price of $0.15 and a 200-day moving average price of $0.83. The company has a debt-to-equity ratio of 34.06, a current ratio of 1.26 and a quick ratio of 0.68. The stock has a market capitalization of $4.81 million, a price-to-earnings ratio of 0.00 and a beta of 0.67.

BIOLASE (NASDAQ:BIOL) last posted its quarterly earnings data on Thursday, March 21st. The medical technology company reported ($1.76) earnings per share for the quarter. BIOLASE had a negative net margin of 41.97% and a negative return on equity of 555.22%. The company had revenue of $13.49 million for the quarter.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of BIOLASE in a research note on Thursday, April 18th. They set a “sell” rating for the company.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.